Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 23;57(20):8249-67.
doi: 10.1021/jm500973a. Epub 2014 Oct 1.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor

M Raymond V Finlay  1 , Mark Anderton, Susan Ashton, Peter Ballard, Paul A Bethel, Matthew R Box, Robert H Bradbury, Simon J Brown, Sam Butterworth, Andrew Campbell, Christopher Chorley, Nicola Colclough, Darren A E Cross, Gordon S Currie, Matthew Grist, Lorraine Hassall, George B Hill, Daniel James, Michael James, Paul Kemmitt, Teresa Klinowska, Gillian Lamont, Scott G Lamont, Nathaniel Martin, Heather L McFarland, Martine J Mellor, Jonathon P Orme, David Perkins, Paula Perkins, Graham Richmond, Peter Smith, Richard A Ward, Michael J Waring, David Whittaker, Stuart Wells, Gail L Wrigley
Affiliations

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor

M Raymond V Finlay et al. J Med Chem. .

Abstract

Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a number of years. Despite encouraging clinical efficacy with these agents, in many patients resistance develops leading to disease progression. In most cases, this resistance is in the form of the T790M mutation. In addition, EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea. We describe herein the evolution of an early, mutant selective lead to the clinical candidate AZD9291, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor. Following observations of significant tumor inhibition in preclinical models, the clinical candidate was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompanied by an encouraging safety profile.

PubMed Disclaimer

MeSH terms